The elongation complex components BRD4 and MLLT3/AF9 are transcriptional coactivators of nuclear retinoid receptors

PLoS One. 2013 Jun 10;8(6):e64880. doi: 10.1371/journal.pone.0064880. Print 2013.

Abstract

Nuclear all-trans retinoic acid receptors (RARs) initiate early transcriptional events which engage pluripotent cells to differentiate into specific lineages. RAR-controlled transactivation depends mostly on agonist-induced structural transitions in RAR C-terminus (AF-2), thus bridging coactivators or corepressors to chromatin, hence controlling preinitiation complex assembly. However, the contribution of other domains of RAR to its overall transcriptional activity remains poorly defined. A proteomic characterization of nuclear proteins interacting with RAR regions distinct from the AF-2 revealed unsuspected functional properties of the RAR N-terminus. Indeed, mass spectrometry fingerprinting identified the Bromodomain-containing protein 4 (BRD4) and ALL1-fused gene from chromosome 9 (AF9/MLLT3), known to associate with and regulates the activity of Positive Transcription Elongation Factor b (P-TEFb), as novel RAR coactivators. In addition to promoter sequences, RAR binds to genomic, transcribed regions of retinoid-regulated genes, in association with RNA polymerase II and as a function of P-TEFb activity. Knockdown of either AF9 or BRD4 expression affected differentially the neural differentiation of stem cell-like P19 cells. Clusters of retinoid-regulated genes were selectively dependent on BRD4 and/or AF9 expression, which correlated with RAR association to transcribed regions. Thus RAR establishes physical and functional links with components of the elongation complex, enabling the rapid retinoid-induced induction of genes required for neuronal differentiation. Our data thereby extends the previously known RAR interactome from classical transcriptional modulators to components of the elongation machinery, and unravel a functional role of RAR in transcriptional elongation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Biomarkers / metabolism
  • Blotting, Western
  • Cell Cycle Proteins
  • Cell Differentiation*
  • Cell Proliferation
  • Chromatin Immunoprecipitation
  • Fluorescent Antibody Technique
  • Gene Expression Profiling
  • HeLa Cells
  • Humans
  • Immunoprecipitation
  • Nuclear Proteins / antagonists & inhibitors
  • Nuclear Proteins / genetics
  • Nuclear Proteins / metabolism*
  • Oligonucleotide Array Sequence Analysis
  • Pluripotent Stem Cells / cytology*
  • Pluripotent Stem Cells / drug effects
  • Pluripotent Stem Cells / metabolism
  • Positive Transcriptional Elongation Factor B / genetics
  • Positive Transcriptional Elongation Factor B / metabolism*
  • Promoter Regions, Genetic / genetics
  • RNA, Messenger / genetics
  • RNA, Small Interfering / genetics
  • Real-Time Polymerase Chain Reaction
  • Receptors, Retinoic Acid / genetics*
  • Receptors, Retinoic Acid / metabolism
  • Reverse Transcriptase Polymerase Chain Reaction
  • Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
  • Transcription Factors / antagonists & inhibitors
  • Transcription Factors / genetics
  • Transcription Factors / metabolism*
  • Transcriptional Activation*
  • Tretinoin / pharmacology

Substances

  • Antineoplastic Agents
  • BRD4 protein, human
  • Biomarkers
  • Cell Cycle Proteins
  • MLLT3 protein, human
  • Nuclear Proteins
  • RNA, Messenger
  • RNA, Small Interfering
  • Receptors, Retinoic Acid
  • Transcription Factors
  • Tretinoin
  • Positive Transcriptional Elongation Factor B

Grants and funding

This work was funded by grants from La Ligue Nationale contre le Cancer (to PL), from European Genomic Institute for Diabetes (E.G.I.D., ANR-10-LABX-46), Contrat Plan Etat-Région “Campus Intelligent” to LH, and ANR “MULtimodal” to LH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.